High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)

F.R. Mauro, S. Molica, S. Soddu, F. Ilariucci, M. Coscia, F. Zaja, E. Angelucci, F. Re, A.M. Liberati, A. Tedeschi, G. Reda, D. Pietrasanta, A. Gozzetti, R. Battistini, G. Del Poeta, C. Musolino, M. Nanni, A. Piciocchi, M. Vignetti, A. NeriF. Albano, A. Cuneo, I.D. Giudice, I.D. Starza, M.S. de Propris, S. Raponi, A.R. Guarini, R. Foà

Research output: Contribution to journalArticlepeer-review

Cite this